Abstract:ObjectivesUsing quantitative coronary angiography (QCA), optical coherence tomography (OCT), histomorphometry, and pharmacokinetics, this study tried to evaluate the safety and efficacy of Biomagic rapamycin-eluting bioabsorbable scaffold (BVS) in non-atherosclerotic porcine coronary arteries.BackgroundBiomagic BVS is a new generation of thin-strut bioabsorbable scaffold. We conducted comparative study detailing pathological response, safety and efficacy of Biomagic BVS and the Firebird2 rapamycin-eluting cobalt-based alloy stent (DES) in a porcine coronary artery model. The animals were followed up at 14 days, 1, 3, 6, 12, 18, 24, 30, 36, 42, 48, 54, and 60 months after stent implantation.MethodsA total of 143 devices (95 Biomagic and 48 Firebird2) were implanted in 2 or 3 main coronary arteries of 76 nonatherosclerotic swine and examined by QCA, OCT, light microscopy, and pharmacokinetics analyses at various time points.ResultsVascular responses to Biomagic and Firebird2 were largely comparable at all time points, with struts being sequestered within the neointima. The degree of inflammation of both devices was mild to moderate, although the Biomagic score was higher at 14 days to 24 months. However, there was no statistical difference between the two groups except 14 days. At each follow-up time point, the percentage of area stenosis in the Biomagic group was greater than that in the Firebird 2 group, but there was no statistical difference between the two groups at 3 and 12 months. The extent of fibrin deposition was similar between Biomagic and Firebird2, which peaked at 1 month and decreased rapidly thereafter. Pharmacokinetic study showed that coronary tissue sirolimus concentration remained above 2 ng/mg of tissue at 28 day. Histomorphometry showed expansile remodeling of Biomagic-implanted arteries starting after 12 months, and lumen area was significantly greater in Biomagic than Firebird2 at 36 and 42 months. These changes correlated with dismantling of Biomagic seen after 12 months. OCT images confirmed that degradation of Biomagic was complete by 36 months.ConclusionsBiomagic demonstrates comparable long-term safety to Firebird2 in porcine coronary arteries with mild to moderate inflammation. Although Biomagic was associated with greater percent stenosis relative to Firebird2 within 36 months, expansile remodeling was observed after 12 months in Biomagic with significantly greater lumen area at ≥36 months. Scaffold resorption is considered complete at 36 months.

Short-term Efficacy of Fully Bioabsorbable Poly-L-Lactic Acid Sirolimus-eluting Scaffold in Porcine Model Assessed by Optical Coherence Tomography

Histological Evaluation of Osteogenesis of 3D-Printed Poly-Lactic-Co-Glycolic Acid (plga) Scaffolds in A Rabbit Model

TCT-431 Long-term Angiographic and Optical Coherence Tomography Follow-up of XINSORB Scaffold in Porcine Coronary Model

A Head to Head Comparison of XINSORB Bioresorbable Sirolimus-Eluting Scaffold Versus Metallic Sirolimus-Eluting Stent: 180 Days Follow-Up in a Porcine Model

Short-term Effects of Fully Bioabsorbable PLLA Coronary Stents in a Porcine Model

Consecutive IVUS Assessment of Acute Recoil of Fully Bioabsorbable Poly-L-Lactic Acid Scaffold Within 4 Weeks in Porcine Model

Comparison of the “late Catch-Up” Phenomenon Between BuMA Supreme and XIENCE Stents Through Serial Optical Coherence Tomography at 1–2 Month and 2 Year Follow-Ups: A Multicenter Study

Six-month Outcomes of the XINSORB Bioresorbable Sirolimus-Eluting Scaffold in Treating Single De Novo Lesions in Human Coronary Artery.

A novel biodegradable polymer-coated cobalt-chromium alloy sirolimus-eluting stent：evaluation in a porcine model

Five-year Comparative Study of Thin-Strut Rapamycin-Eluting Bioabsorbable Scaffold with Metallic Drug-Eluting Stent in Porcine Coronary Artery

Safety and Efficacy of Cobalt Chromium Alloy Based Sirolimus-Eluting Stent with Bioabsorbable Polymer in Porcine Model.

Long-Term Efficacy, Safety and Biocompatibility of a Novel Sirolimus Eluting Iron Bioresorbable Scaffold in a Porcine Model

AS-30: the Preclinical Assessment of a Novel Biodegradable Rapid Prohealing Polymer with Sirolimus -Eluting Coating Stent in Porcine Model

Assessment of an Asymmetrical Coating Stent with Sirolimus Released from Ablumial Matrix in Porcine Model

In vivo degradation and endothelialization of an iron bioresorbable scaffold

A Biodegradable-Polymer-plga-coated,sirolimus-eluting Cobalt-chromium Alloy Stent:Safety and Efficacy Evaluation in a Porcine Model

A novel biodegradable polymer coated,sirolimus-eluting stent: evaluation in a porcine coronary model

Twelve-month Angiographic and Clinical Outcomes of the XINSORB Bioresorbable Sirolimus-Eluting Scaffold and a Metallic Stent in Patients with Coronary Artery Disease

Effectiveness and safety of the sirolimus-eluting stents coated with bioabsorbable polymer coating in human coronary arteries.

Long-Term Effects of Novel Biodegradable, Polymer-Coated, Sirolimus-Eluting Stents on Neointimal Formation in A Porcine Coronary Model

5 Years of Serial Intravascular Imaging Outcomes of XINSORB Sirolimus-Eluting Bioresorbable Vascular Scaffold.